Trial · NCT04625283

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

NCT04625283, Phase 4, Completed, Vanderbilt University Medical Center; results first posted 2025-02-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Impact of Perioperative Ketamine Infusion on Surgical Recovery. Trials, record NCT04625283. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04625283

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Impact of Perioperative Ketamine Infusion on Surgical Recovery
NCT number: NCT04625283
Status: Completed
Phases: Phase 4
Enrollment: 1,570 participants, actual
Lead sponsor: Vanderbilt University Medical Center
Conditions: Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions: Ketamine, Placebo
First posted: 2020-11-12
Last updated: 2025-02-04
Results first posted: 2025-02-04

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Length of Stay	From surgery start until discharge, typically 3-5 days	The participants length of stay, from anesthesia beginning to discharge, measured in days
Secondary	Total Consumption of Inpatient Opioids	From hospital admission until discharge, typically 3-5 days	Inpatient opioid consumption measured in morphine milligram equivalents
Secondary	Number of Participants With Ileus	From hospital admission until discharge, typically 3-5 days	Number of participants reporting ileus requiring gastric decompression as defined by orogastric or nasogastric tube placement in the postoperative period.
Secondary	Number of Participants Who Encounter Rapid Response Team Activation	From hospital admission until discharge, typically 3-5 days	Number of participants who encounter rapid response team activation within 72 hours post-operation. This is as a binary outcome
Secondary	Number of Participants Who Experienced ICU Transfer	From hospital admission until discharge, typically 3-5 days	Number of participants who experienced transfer to ICU. This is as a binary outcome
Secondary	Number of Participants Who Experienced Adverse Side Effects	From hospital admission until discharge, typically 3-5 days	Total number of side effects (hallucination, sedation, lightheadedness, patient request) as adverse reactions requiring early cessation.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Length of Stay	From surgery start until discharge, typically 3-5 days	days	MEDIAN
SECONDARY	Total Consumption of Inpatient Opioids	From hospital admission until discharge, typically 3-5 days	MME	MEDIAN
SECONDARY	Number of Participants With Ileus	From hospital admission until discharge, typically 3-5 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Who Encounter Rapid Response Team Activation	From hospital admission until discharge, typically 3-5 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Who Experienced ICU Transfer	From hospital admission until discharge, typically 3-5 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Who Experienced Adverse Side Effects	From hospital admission until discharge, typically 3-5 days	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Length of Stay	Ketamine	5.0	Inter-Quartile Range 4.0 to 8.0	days
Length of Stay	Saline	5.0	Inter-Quartile Range 3.0 to 7.2	days
Total Consumption of Inpatient Opioids	Ketamine	82.5	Inter-Quartile Range 37.5 to 158.0	MME
Total Consumption of Inpatient Opioids	Saline	90.0	Inter-Quartile Range 45.0 to 158.0	MME
Number of Participants With Ileus	Ketamine	71		Participants
Number of Participants With Ileus	Saline	37		Participants
Number of Participants Who Encounter Rapid Response Team Activation	Ketamine	39		Participants
Number of Participants Who Encounter Rapid Response Team Activation	Saline	26		Participants
Number of Participants Who Experienced ICU Transfer	Ketamine	44		Participants
Number of Participants Who Experienced ICU Transfer	Saline	22		Participants

1 to 10 of 22Source ClinicalTrials.gov

See all 22 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ketamine	798
Overall Study	STARTED	Saline	772
Overall Study	COMPLETED	Ketamine	770
Overall Study	COMPLETED	Saline	752
Overall Study	NOT COMPLETED	Ketamine	28
Overall Study	NOT COMPLETED	Saline	20

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Patient Preference forMild Side Effects	General disorders	Ketamine	83	770
other	Patient Preference forMild Side Effects	General disorders	Saline	39	752
other	Debilitating Hallucinations	Psychiatric disorders	Ketamine	19	770
other	Debilitating Hallucinations	Psychiatric disorders	Saline	7	752
other	Debilitating Dizziness	Nervous system disorders	Ketamine	64	770
other	Debilitating Dizziness	Nervous system disorders	Saline	11	752
other	Hemodynamic Instability	Vascular disorders	Ketamine	12	770
other	Hemodynamic Instability	Vascular disorders	Saline	6	752
other	Rapid Response Activation	General disorders	Ketamine	39	770
other	Rapid Response Activation	General disorders	Saline	26	752

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ketamine	1	770
Total, all-cause mortality	Saline	0	752
Total, other adverse events	Ketamine	322	770
Total, other adverse events	Saline	163	752
Total, serious adverse events	Ketamine	0	770
Total, serious adverse events	Saline	1	752

Source ClinicalTrials.gov

Papers25

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
19923527	BACKGROUND	PubMed
22374377	BACKGROUND	PubMed
23814653	BACKGROUND	PubMed
24368573	BACKGROUND	PubMed
26283834	BACKGROUND	PubMed
26855773	BACKGROUND	PubMed
28403427	BACKGROUND	PubMed
28673215	BACKGROUND	PubMed
29555468	BACKGROUND	PubMed
29750324	BACKGROUND	PubMed

1 to 10 of 25

See all 25 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ketamine vs Saline: Number of Participants Who Experienced ICU Transfer	Trial comparisons
Ketamine vs Saline: Number of Participants With Ileus	Trial comparisons
Ketamine vs Saline: Number of Participants Who Encounter Rapid Response Team Activation	Trial comparisons
Ketamine vs Saline: deaths from any cause	Trial comparisons
Ketamine vs Saline: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04625283

GET https://conductscience.org/api/trials/v1/NCT04625283/results?page=2

API reference For AI assistants